Recombinant IFNA2 antibody

Catalog No. ABIN7852051

The Human Chimeric anti-IFNA2 antibody is suitable to detect IFNA2 in samples from Human. It has been validated for FACS.

Quick Overview for Recombinant IFNA2 antibody (ABIN7852051)

Target: IFNA2 (Interferon, alpha 2 (IFNA2))

Antibody Type: Recombinant Antibody

Fragment: Fc fragment

Reactivity: Human

Host: Human, Rabbit

Clonality: Chimeric

Conjugate: This IFNA2 antibody is un-conjugated

Application: Flow Cytometry (FACS)

Clone: 1B7

Product Details anti-IFNA2 Antibody

Purpose: Anti-IFNA2 antibody(1B7), IgG1 Chimeric mAb

Purification: Purified from cell culture supernatant by affinity chromatography

Isotype: IgG1

Application Details

Application Notes: Flow Cyt 1/100

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Please see Certificate of Analysis for specific instructions of reconstitution.

Buffer: Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose is added as protectants before lyophilization.

Storage: -20 °C,-80 °C

Storage Comment: Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.

Expiry Date: 12 months

Target Details for IFNA2

Target: IFNA2 (Interferon, alpha 2 (IFNA2))

Alternative Name: IFNA2

Background: This gene is a member of the alpha interferon gene cluster on chromosome 9. The encoded cytokine is a member of the type I interferon family that is produced in response to viral infection as a key part of the innate immune response with potent antiviral, antiproliferative and immunomodulatory properties. This cytokine, like other type I interferons, binds a plasma membrane receptor made of IFNAR1 and IFNAR2 that is ubiquitously expressed, and thus is able to act on virtually all body cells. The encoded protein is effective in reducing the symptoms and duration of the common cold and in treating many types of cancer, including some hematological malignancies and solid tumors. A deficiency of type I interferon in the blood is thought to be a hallmark of severe COVID-19 and may provide a rationale for a combined therapeutic approach. [provided by RefSeq, Aug 2020]

UniProt: P01563

Pathways: JAK-STAT Signaling, Regulation of Leukocyte Mediated Immunity, Production of Molecular Mediator of Immune Response, Hepatitis C